Species |
Human |
Protein Construction |
IL-17C (His19-Val197) Accession # Q9P0M4 |
His |
Avi |
N-term |
|
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by SECHPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-17C, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind Human IL17RE, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
22.6 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-28 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl (PH 6.0). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl (PH 6.0). |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
Interleukin‑17C (IL‑17C) is a 15‑20 kDa glycosylated cytokine that plays an important role in mucosal immunity and chronic inflammation. The six IL‑17 cytokines (IL‑17A‑F) are encoded by separate genes but adopt a conserved cystine knot fold. IL‑17C is Cytokine that plays a crucial role in innate immunity of the epithelium, including to intestinal bacterial pathogens, in an autocrine manner. Stimulates the production of antibacterial peptides and proinflammatory molecules for host defense by signaling through the NF-kappa-B and MAPK pathways. Acts synergically with IL22 in inducing the expression of antibacterial peptides, including S100A8, S100A9, REG3A and REG3G. |
Synonyms |
CX2; Cytokine CX2; IL17C; IL-17C; IL-17CMGC126884 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.